Association of early PSA decline and time to PSA progression in abiraterone acetate-treated metastatic castration-resistant prostate cancer; a post-hoc analysis of Japanese phase 2 trials

BACKGROUND: Previous studies have demonstrated an association between prostate-specific antigen (PSA) kinetics and predictive value for treatment outcomes. Abiraterone acetate (AA) is a newly approved cytochrome-P450C17 inhibitor for treatment of metastatic castration-resistant prostate cancer (mCRP...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakayama, Masahiko, Kobayashi, Hisanori, Takahara, Tomihiro, Oyama, Ryo, Imanaka, Keiichiro, Yoshizawa, Kazutake
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4898460/
https://www.ncbi.nlm.nih.gov/pubmed/27278777
http://dx.doi.org/10.1186/s12894-016-0148-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4898460/
https://www.ncbi.nlm.nih.gov/pubmed/27278777
http://dx.doi.org/10.1186/s12894-016-0148-4

Ejemplares similares